A Two-part, Randomized, Double-blind, Placebo-controlled, Single Dose Study of BCT197 for the Prevention of Acute Kidney Injury (AKI) in Patients Undergoing Elective Cardiac Surgery With Cardiopulmonary Bypass (CPB)
| City: |
|
Lincoln |
| State: |
|
Nebraska |
| Zip Code: |
|
68506 |
| Conditions: |
|
Acute Kidney Injury |
| Purpose: |
|
This study will assess the safety and efficacy of BCT197 on acute kidney injury in patients
undergoing cardiac surgery with cardiopulmonary bypass.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Patients scheduled for elective cardiac surgery with CPB. Allowable procedures are
CABG alone, aortic valve replacement or repair alone, mitral valve replacement or
repair alone, CABG with aortic valve replacement or repair, and CABG with mitral
valve replacement or repair. Patients with repeat surgery for any of the procedures
can be included.
- Patients must weigh at least 50 kg to participate in the study, and must have a body
mass index (BMI) 18 kg/m2
- Have an eGFR ≥ 30 and ≤ 60 mL/min/1.73 m2 to participate in Part A, or an eGFR > 60
mL/min/1.73 m2 to participate in Part B. Upon completion of Part A, patients with
eGFR ≥ 30 mL/min/1.73 m2 may participate in Part B, with dose administered as per the
dosing table
Exclusion Criteria:
- left ventricular ejection fraction, in the last 6 months, ≥30%
- Active systemic infection or uncontrolled diabetes mellitus with a glucose ≥250 mg%
at the screening assessment
- Pregnant or nursing (lactating) women,
- Female subjects must either:
have been surgically sterilized or hysterectomized at least 6 months prior to study
participation, or have had surgical bilateral oophorectomy (with or without hysterectomy)
or tubal ligation at least six weeks prior to study participation. In the case of
oophorectomy alone, only when the reproductive status of the woman has been confirmed by
follow - up hormone level assessment is she considered not of child bearing potential,
Surgical sterilization procedures or hysterectomy must be supported with clinical
documentation made available to the sponsor and noted in the Relevant Medical History /
Current Medical Conditions section of the CRF, OR be postmenopausal. Female subjects are
considered post-menopausal and not of child bearing potential if they have had 12 months
of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age
appropriate, history of vasomotor symptoms). Female subjects 60 years of age or younger
must confirm menopause by the demonstration of a plasma FSH level in the postmenopausal
range according to the lab normal range. Documentation of a prior plasma FSH level is
acceptable
- History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of
drug abuse as indicated by the laboratory assays conducted during screening or
baseline
- New cancer diagnosis with planned chemotherapy and/or radiation therapy, or cancer
requiring ongoing chemotherapy and/or radiation therapy at the time of screening .•
Other protocol-defined inclusion/exclusion criteria may apply
|
| NCT ID: |
|
NCT01336959 |
| Primary Contact: |
|
Study Director
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Phone: +1(862)778-8300
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Lincoln, Nebraska 68506
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|